Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 3 Simplified EULAR and GRAPPA

Published byArchibald Malone Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 3 Simplified EULAR and GRAPPA"— Presentation transcript:

1 Figure 3 Simplified EULAR and GRAPPA
treatment algorithms for predominant axial psoriatic arthritis5,6 Figure 3 | Simplified EULAR and GRAPPA treatment algorithms for predominant axial psoriatic arthritis5,6. The order of drug use proposed for patients with psoriatic arthritis (PsA) and predominant axial involvement, with a step-up approach (indicated by staggered boxes) in case of inefficacy and/or toxicity. *Conditional recommendation in the GRAPPA guidelines for drugs without current regulatory approval or where recommendations are based on abstract data only. bDMARD, biologic DMARD; EULAR, European League Against Rheumatism; GRAPPA, Group for Research and Assessment of Psoriasis and Psoriatic Arthritis. Gossec, L. et al. (2016) Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations Nat. Rev. Rheumatol. doi: /nrrheum

Download ppt "Figure 3 Simplified EULAR and GRAPPA"

Similar presentations

GRAPPA Guidelines for PsA: Considerations

GRAPPA Guidelines for PsA: Considerations
Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum
Psoriatic Arthritis.

Psoriatic Arthritis.
Summary of TB cases across indications and trial periods

Summary of TB cases across indications and trial periods
Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.
Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation.

Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation.
Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum
Figure 1 Enthesitis versus synovitis

Figure 1 Enthesitis versus synovitis
Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum
Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum
Figure 1 Induction of immune tolerance

Figure 1 Induction of immune tolerance
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum
Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum
Figure 2 Targeted versus untargeted metabolomics approaches

Figure 2 Targeted versus untargeted metabolomics approaches
Figure 1 Metabolic profiling as a tool for studying rheumatic diseases

Figure 1 Metabolic profiling as a tool for studying rheumatic diseases
Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway
Figure 2 Simplified EULAR and GRAPPA

Figure 2 Simplified EULAR and GRAPPA
Figure 3 Transcriptome studies performed in the target

Figure 3 Transcriptome studies performed in the target

Similar presentations

Ads by Google